Association of TNFA (j308G>A) and IL-10 (j819C>T) promoter polymorphisms with risk of cervical cancer

International Journal of Gynecological Cancer

Volumn 19, Issue 7, 2009, Pages 1190-1194

  Singh, Hariom ^a   Jain, Meenu ^a   Sachan, Rekha ^b   Mittal, Balraj ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^b KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Cervical cancer; Genetic polymorphism; Interleukin 10; TNFA

Indexed keywords

INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA; IL10 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; UTERINE CERVIX CANCER; CARCINOMA; ENVIRONMENT; GENETIC LINKAGE; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOLOGY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; UTERINE CERVIX TUMOR;

ADULT; CARCINOMA; DNA MUTATIONAL ANALYSIS; ENVIRONMENT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-10; LINKAGE (GENETICS); MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA; UTERINE CERVICAL NEOPLASMS;

EID: 73449101521     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a3a3af     Document Type: Article

References (38)

1. Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153-156. (Pubitemid 32911406)
2. Sankaranarayanan R, Nene BM, Dinshaw K, et al. Early detection of cervical cancer with visual inspection methods: a summary of completed and on-going studies in India. Salud Publica Mex. 2003;45:S274-S282.
3. Pinto LA, Castle PE, Roden RB, et al. HPV-16 LI VLP vaccine elicits abroad-spectrum of cytokine responses in whole blood. Vaccine. 2005;23:3555-3564.
4. Bidwell J, Keen L, Gallagher G, et al. Cytokine gene polymorphism in human disease: on-line databases. Genes Immun. 1999;1:3-19.
5. Marsh HP, Haldar NA, Bunce M, et al. Polymorphisms in tumor necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumor at presentation. Br J Cancer. 2003;89:1096-1101.
6. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med. 1993;328:106-113.
7. Tracey KJ, Cerami A. Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol. 1993;9:317-343.
8. Chen G,Wilson R,Wang SH, et al. Tumor necrosis factor alpha (TNF->) gene polymorphism and expression in pre-eclampsia. Clin Exp Immunol. 1996;104:154-159.
9. Kroeger KM, Carville KS, Abraham LJ. The-308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol. 1997;34:391-399.
10. Ghaderi M, Nikitina L, Peacock CS, et al. Tumor necrosis factor a-11 and DR15-DQ6 (B.*0602) haplotype increase the risk for cervical intraepithelial neoplasia in human papillomavirus 16 seropositive women in Northern Sweden. Cancer Epidemiol Biomarkers Prev. 2000;9:1067-1070.
11. Calhoun ES, McGovern RM, Janney CA, et al. Host genetic polymorphism analysis in cervical cancer. Clin Chem. 2002;48:1218-1224.
12. Stanczuk GA, Sibanda EN, Tswana SA, et al. Polymorphism at the -308-promoter position of the tumor necrosis factor alpha (TNF-alpha) gene and cervical cancer. Int J Gynecol Cancer. 2003;13:148-5336.
13. Deshpande A, Nolan JP, White PS, et al. TNF-a promoter polymorphisms and susceptibility to human papillomavirus 16-associated cervical cancer. J Infect Dis. 2005;191:969-976.
14. Govan V, Constant D, Hoffman M, et al. The allelic distribution of -308 tumor necrosis factor-alpha gene polymorphism in South African women with cervical cancer and control women. BMC Cancer. 2006;6:2407-2424.
15. Kohaar I, Thakur N, Salhan S, et al. TNFα-308G/A polymorphism as a risk factor for HPV associated cervical cancer in Indian population. Cell Oncol. 2007;29:249-256.
16. de Waal Malefyt R, Abrams J, et al. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991;174:1209-1220.
17. Fiorentino DF, Zlotnik A, Mosmann TR, et al. IL-10 inhibits cytokine production by activated macrophages. J Immunol. 1991;147: 3815-3822.
18. Takeshita S, Gage JR, Kishimoto T, et al. Differential regulation of IL-6 gene transcription and expression by IL-4 and Il-10 in human monocytic cell lines. J Immunol. 1996;156:2591-2598.
19. Perrey C, Pravica V, Sinnott PJ, et al. Genotyping for polymorphisms in interferon-gamma, interleukin-10, transforming growth factor-beta 1 and tumor necrosis factor-alpha genes: a technical report. Transpl Immunol. 1998;6:193-197.
20. Kube D, Rieth H, Eskdal J, et al. Structural characterization of the distal 50 flanking region of the human interleukin-10 gene. Genes Immun. 2001;2:181-190.
21. Giannini SL, Al-Saleh W, Piron H, et al. Cytokine expression in squamous intraepithelial lesions of the uterine cervix: implications for the generation of local immunosuppression. Clin Exp Immunol. 1 998; 113:183-189.
22. Jacobs N, Giannini SL, Doyen J, et al. Inverse modulation of IL-10 and IL-12 in the blood of women with preneoplastic lesions of uterine cervix. Clin Exp Immunol. 1998;111:219-224.
23. de Gruijl TD, Bontkes HJ, van den Muysenberg AJ, et al. Differences in cytokine mRNA profiles between premalignant and malignant lesions of the uterine cervix. Eur J Cancer. 1999;35:490-497.
24. Roh JW, Kim MH, Seo SS, et al. Interleukin-10 promoter polymorphisms and cervical cancer risk in Korean women. Cancer Lett. 2002;184:57-63.
25. Miller SA, Dykes DD, Polesky HF. A salting procedure for extracting DNA from nucleated cells. Nucleic Acid Res. 1998;16:1215.
26. Rad R, Dossumbekova A, Neu B, et al. Cytokine gene polymorphism influence mucosal cytokine expression, gastric inflammation and host specific colonization during Helicobacter pylori infection. Gut. 2004;53:1082-1089.
27. Achyut BR, Tripathi P, Ghoshal UC, et al. Interleukin-10 (-819 C/T) and tumor necrosis factor-alpha (-308 G/A) gene variants influence gastritis and lymphoid follicle development. Dig Dis Sci. 2008;53:622-629.
28. Duarte I, Santos A, Sousa H, et al. G-308A TNF-α polymorphism is associated with an increased risk of invasive cervical cancer. Biochem Biophys Res Commun. 2005;334:588-592.
29. Craig D, Woodwor T, Mcmullin E, et al. Interleukin la and tumor necrosis factor a stimulate autocrine amphiregulin expression and proliferation of human papillomavirus-immortalized and carcinoma-derived cervical epithelial cells. Proc Natl Acad Sci U S A. 1995;92:2840-2844.
30. Furuta T, El-Omar EM, Xiao F, et al. Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology. 2002; 123:92-105.
31. Schmauz R, Okong P, de Villiers EM, et al. Multiple infections in cases of cervical cancer from a high-incidence area in tropical Africa. Int J Cancer. 1989;43:805-809.
32. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med. 1992;327:1272-1278.
33. Hallermalm K, Seki K, Wei C, et al. Tumor necrosis factor-a induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface. Blood. 2001;98:1108-1115.
34. De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol. 2004;50:187-196.
35. Zoodsma M, Nolte IM, Schipper M, et al. Methylenetetrahydrofolate reductase (MTHFR) and susceptibility for (pre)neoplastic cervical disease. Hum Genet. 2005;116:247-254. (Pubitemid 40277235)
36. Goodman MT, McDuffie K, Hernandez B, et al. Association of methylenetetrahydrofolate reductase polymorphism C677T and dietary folate with the risk of cervical dysplasia. Cancer Epidemiol Biomarkers Prev. 2001;10:1275-1280.
37. Kataja V, Syrjänen S, Yliskoski M, et al. Risk factors associated with cervical human papillomavirus infections: a case control study. Am J Epidemiol. 1993;138:735-745.
38. Wong M, Ziring D, Korin Y, et al. TNFα blockade in human diseases: Mechanisms and future directions. Clin Immunol. 2008;126:13-30.